CENTRE FOR DRUG DESIGN & DISCOVERY (CD3)
The Centre for Drug Design and Discovery (CD3) is an investment fund and technology transfer platform aimed at promoting the discovery and development of innovative medicines for all kinds of diseases. CD3 achieves this goal by building further on the enormous pool of basic knowledge, innovation and technology of universities and spin-off companies. By providing the necessary expertise and financial resources, CD3 ensures that fundamental biomedical research carried out by universities and small... biotech companies is translated into more usable results and promising molecules for new medicines. These new, potential medicines can then be further developed by pharmaceutical companies or form the basis for new spin-off companies. With this work method and philosophy, CD3 bridges the gap between academic innovative research and the pharmaceutical industry.
CENTRE FOR DRUG DESIGN & DISCOVERY (CD3)
Industry:
Biopharma Biotechnology Health Care Medical
Address:
Leuven, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.cd3.eu
Status:
Active
Contact:
(321)632-6484
Email Addresses:
[email protected]
Technology used in webpage:
Domain Not Resolving IPv6 Google Maps API
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Okairos
Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
OxiProteomics
OxiProteomics is a technology-based start-up committed to promoting the healthy living and healthy aging of human population.
SensAbues AB
SensAbues has the ultimate technology for drug testing non invasive and non intrusive!.
Current Employees Featured
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2018-01-04 | Rewind Therapeutics | Centre for Drug Design & Discovery (CD3) investment in Series A - Rewind Therapeutics | 15.2 M EUR |
Official Site Inspections
http://www.cd3.eu
- Host name: web-rewrites.icts.kuleuven.be
- IP address: 134.58.64.162
- Location: Leuven Belgium
- Latitude: 50.8758
- Longitude: 4.7027
- Timezone: Europe/Brussels
- Postal: 3000